Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Effexor · 5 trials · 1 indication
Bioequivalence based on Venlafaxine Cmax (maximum observed concentration of drug substance in plasma).
Bioequivalence based on Venlafaxine AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).
Bioequivalence based on Venlafaxine AUC0-inf (area under the concentration-time curve from time zero to infinity).
Bioequivalence based on Cmax
Bioequivalence based on AUC0-inf
Bioequivalence based on AUC0-t
| Arm | Type | Description |
|---|---|---|
| Investigational Test Product | EXPERIMENTAL | Venlafaxine Hydrochloride 150 mg Extended-Release Capsules. |
| Reference Listed Drug | ACTIVE_COMPARATOR | Effexor® XR 150 mg Extended-Release Capsules |
| Venlafaxine | EXPERIMENTAL | Venlafaxine 25 mg Tablet (test) dosed in first period followed by Effexor® 25 mg Tablet (reference) dosed in second period |
| Effexor® | ACTIVE_COMPARATOR | Effexor® 25 mg Tablet (reference) dosed in first period followed by Venlafaxine 25 mg Tablet (test) dosed in second period |
| Name | Type | Description |
|---|---|---|
| Venlafaxine Hydrochloride | DRUG | 150 mg Extended-Release Capsule |
| Effexor® XR | DRUG | 150 mg Extended-Release Capsule |
| Venlafaxine 25 mg Tablets | DRUG | 1 x 25 mg, single-dose fasting |
| Effexor® 25 mg Tablets | DRUG | 1 x 25 mg, single-dose fasting |
Inclusion Criteria: * Members of the community at large. * Subjects will be females and/or males, non-smokers, 18 years of age and older. * Female subjects will be postmenopausal or surgically sterilized. Exclusion Criteria: * Clinically significant illness within 4 weeks of the administration of...
Effexor is a small molecule drug being developed by Teva Pharmaceutical Industries Limited (TEVA). It is currently in Phase 1 clinical development. The drug is being studied in healthy volunteers for research purposes, with completed trials focusing on the pharmacokinetics of venlafaxine tablets and extended-release capsules.
Effexor is being studied in healthy volunteers as part of Phase 1 clinical trials. These trials are designed to evaluate the drug's absorption and effects under fasting and fed conditions, as well as a sprinkle administration study. The drug is not yet approved for any specific medical condition.
Effexor is being developed by Teva Pharmaceutical Industries Limited, a company traded under the ticker TEVA. Teva is conducting Phase 1 clinical trials of the drug in healthy volunteers in Canada, with all five trials completed.
Effexor is in Phase 1 clinical development. All five clinical trials associated with the drug are completed, with no active trials currently ongoing. The trials enrolled a total of 114 healthy participants and were conducted in Canada.
Effexor has five completed Phase 1 clinical trials, including NCT00834964, NCT01260896, NCT01282801, and NCT01282814. These studies evaluated venlafaxine 25 mg tablets and 150 mg extended-release capsules under fasting, fed, and sprinkle conditions in healthy volunteers.
Effexor is the brand name for venlafaxine, a small molecule drug. The clinical trials for Effexor are listed under the generic name venlafaxine, including studies of venlafaxine 25 mg tablets and venlafaxine hydrochloride 150 mg extended-release capsules.